89bio (ETNB) Total Operating Expense : $303.86 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is 89bio Total Operating Expense?

89bio's Total Operating Expense for the three months ended in Sep. 2024 was $151.94 Mil. 89bio's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $303.86 Mil.

89bio Total Operating Expense Historical Data

The historical data trend for 89bio's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio Total Operating Expense Chart

89bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Operating Expense

Get a 7-Day Free Trial

26.64

49.36

89.74

102.25

151.20

89bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Operating Expense	Get a 7-Day Free Trial															39.35	41.21	57.28	53.44	151.94

89bio Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $303.86 Mil.

89bio Total Operating Expense Related Terms

Thank you for viewing the detailed overview of 89bio's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

89bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104

Website

https://www.89bio.com

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Executives

Rohan Palekar	director, officer: Chief Executive Officer	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Quoc Le-nguyen	officer: See Remarks	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen Laporte	director
Atkinson Edward Morrow Iii	director	C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Ryan Martins	officer: Chief Financial Officer	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd	officer: See Remarks	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg	director, 10 percent owner	100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz	director, 10 percent owner	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026